Literature DB >> 21940817

Fifty years of "the pill": risk reduction and discovery of benefits beyond contraception, reflections, and forecast.

Kristina D Chadwick1, Ronald T Burkman, Belen M Tornesi, Brinda Mahadevan.   

Abstract

Widely regarded as a revolutionary drug in its early years, "the pill" may be considered the first designer or lifestyle drug. Approximately 85% of women in the United States will use an oral contraceptive (OC) for an average of 5 years. Since the introduction of OCs in the 1960s, both health benefits and safety concerns have been attributed to their use. Widespread use of OC formulations by women throughout their reproductive life cycle gave rise to concerns about the effects of OCs on risk factors for cardiovascular disorders and cancer. In most instances, the noncontraceptive benefits of OCs outweigh the potential risks. As with many first in class drugs, lessons can be learned from its development and use. Indeed, "the pill" played a significant role in reshaping the regulatory process for new drugs during the second half of the 20th century. The birth control pill celebrates its 50th birthday this year, as women and men celebrate five decades of this revolutionary method of family planning. Recent scientific and technological advances in genomics, proteomics, new materials, and new drug delivery systems, along with a new understanding of reproductive biology, offer the promise of new, safe, and effective forms of contraception. In addition to the history of OC therapeutic advances and unintended side effects, the noncontraceptive health benefits that women experience beyond pregnancy prevention are discussed. This article summarizes a symposium presented at the 50th Anniversary of the Society of Toxicology National Meeting, held from 6 to 10 March 2011 in Washington, DC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940817     DOI: 10.1093/toxsci/kfr242

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  9 in total

Review 1.  The effects of ethinylestradiol and progestins ("the pill") on cognitive function in pre-menopausal women.

Authors:  Andrea Gogos; YeeWen Candace Wu; Amy S Williams; Linda K Byrne
Journal:  Neurochem Res       Date:  2014-09-30       Impact factor: 3.996

2.  Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.

Authors:  Natasha Larivée; Samy Suissa; Janie Coulombe; Vicky Tagalakis; Kristian B Filion
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

3.  Understanding the cognitive impact of the contraceptive estrogen Ethinyl Estradiol: tonic and cyclic administration impairs memory, and performance correlates with basal forebrain cholinergic system integrity.

Authors:  Sarah E Mennenga; Julia E Gerson; Stephanie V Koebele; Melissa L Kingston; Candy W S Tsang; Elizabeth B Engler-Chiurazzi; Leslie C Baxter; Heather A Bimonte-Nelson
Journal:  Psychoneuroendocrinology       Date:  2015-01-12       Impact factor: 4.905

4.  Cortisol effects on fear memory reconsolidation in women.

Authors:  Shira Meir Drexler; Christian J Merz; Tanja C Hamacher-Dang; Oliver T Wolf
Journal:  Psychopharmacology (Berl)       Date:  2016-05-02       Impact factor: 4.530

5.  Race-Ethnic Differences in Sexual Health Knowledge.

Authors:  Karen Benjamin Guzzo; Sarah R Hayford
Journal:  Race Soc Probl       Date:  2012-09-07

6.  Estradiol effects on spatial memory in women.

Authors:  Soniya Assudani Patel; Karyn M Frick; Paul A Newhouse; Robert S Astur
Journal:  Behav Brain Res       Date:  2021-09-22       Impact factor: 3.332

7.  HIV Status and Contraceptive Utilization among Women in Cameroon.

Authors:  Henna Budhwani; Kristine Ria Hearld; Jodie Dionne-Odom; Simon Manga; Kathleen Nulah; Michelle Khan; Thomas Welty; Edith Welty; Alan Thevenet Tita
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

8.  Prospective, randomized, double-blind, placebo-controlled phase IIa clinical trial on the effects of an estrogen-progestin combination as add-on to inpatient psychotherapy in adult female patients suffering from anorexia nervosa.

Authors:  Georgios Paslakis; Stefanie Maas; Bernd Gebhardt; Andreas Mayr; Manfred Rauh; Yesim Erim
Journal:  BMC Psychiatry       Date:  2018-04-10       Impact factor: 3.630

9.  Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950-2050.

Authors:  Houssein H Ayoub; Ibtihel Amara; Susanne F Awad; Ryosuke Omori; Hiam Chemaitelly; Laith J Abu-Raddad
Journal:  Open Forum Infect Dis       Date:  2021-04-29       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.